基本信息
浏览量:727
职业迁徙
个人简介
Dr. Andreeff has been a pioneer in flow cytometry since 1971, when he established the first flow cytometry laboratory at the University of Heidelberg,and organized the first European conference on flow cytometry. In 1977 he joined Memorial Sloan-Kettering Cancer Center in New York, NY, became head of the Leukemia Cell Biology and Hematopathology Flow Cytometry Laboratory, organized the first Clinical Cytometry Conference in 1986 and the first Molecular Cytogenetics Conference in 1990.
He is Professor of Medicine and holds the Paul and Mary Haas Chair in Genetics at The University of Texas MD Anderson Cancer Center. He has received uninterrupted NCI funding for over 30 years, serves as Principal Investigator of the P01 grant entitled “The Therapy of AML”, participates as Principal Investigator in the MD Anderson Cancer Center Leukemia, Lymphoma, Ovarian and Breast Cancer SPORE grants, the CML P01 and additional R21 and R01 grants. He has published over 639 peer-reviewed papers, 5 books and 75 book chapters
Dr Andreeff’s group has worked extensively on drug resistance in hematopoietic malignancies and breast cancer and developed or co-developed several new therapeutic agents including the novel triterpenoids CDDO and CDDO-Me and Bcl-2-, XIAP-, surviving-, MEK- and HDM2- inhibitors. Over the last decade, his group has made major contributions to the understanding of micro-environment-mediated drug resistance and developed strategies to exploit the underlying mechanisms for the treatment of hematopoietic and epithelial malignancies. His group reported the role of bone marrow-derived multipotent mesenchymal stromal cells (MSC) in tumor stroma formation and developed therapeutic strategies based on this discovery.
He is Professor of Medicine and holds the Paul and Mary Haas Chair in Genetics at The University of Texas MD Anderson Cancer Center. He has received uninterrupted NCI funding for over 30 years, serves as Principal Investigator of the P01 grant entitled “The Therapy of AML”, participates as Principal Investigator in the MD Anderson Cancer Center Leukemia, Lymphoma, Ovarian and Breast Cancer SPORE grants, the CML P01 and additional R21 and R01 grants. He has published over 639 peer-reviewed papers, 5 books and 75 book chapters
Dr Andreeff’s group has worked extensively on drug resistance in hematopoietic malignancies and breast cancer and developed or co-developed several new therapeutic agents including the novel triterpenoids CDDO and CDDO-Me and Bcl-2-, XIAP-, surviving-, MEK- and HDM2- inhibitors. Over the last decade, his group has made major contributions to the understanding of micro-environment-mediated drug resistance and developed strategies to exploit the underlying mechanisms for the treatment of hematopoietic and epithelial malignancies. His group reported the role of bone marrow-derived multipotent mesenchymal stromal cells (MSC) in tumor stroma formation and developed therapeutic strategies based on this discovery.
研究兴趣
论文共 2043 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer Researchno. 9_Supplement (2024): PO2-24
CANCER DISCOVERYno. 7 (2023): 1656-1677
Jer-Yen Yang,Chun-Ju Chang,Weiya Xia,Yan Wang,Kwok-Kin Wong, Jeffrey A. Engelman,Yi Du,Michael Andreeff,Gabriel N. Hortobagyi,Mien-Chie Hung
crossref(2023)
Abhishek Maiti,Muharrem Muftuoglu,James J. Ignatz-Hoover,Courtney D. DiNardo,Farhad Ravandi,Michael Andreeff,Lianchun Xiao,Xuelin Huang,Keyur P. Patel, Jason B Litten, Eliot Bourk, Stephanie Astrow,
Blood (2023): 4863
Abhishek Maiti,Muharrem Muftuoglu,James J. Ignatz-Hoover,Courtney D. DiNardo,Farhad Ravandi,Michael Andreeff,Lianchun Xiao,Xuelin Huang,Keyur P. Patel, Jason B. Litten, Eliot Bourk, Stephanie Astrow,
BLOOD (2023)
Research squareno. 6 (2023): 1-11
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn